OBJECTIVES: Genital warts (GW), 90% of which are caused by human papillomavirus (HPV) types 6 and 11, are a significant problem in the UK. The cost of managing GW in 2010 was previously estimated at £52.4 million. The objective of this study was to estimate the cost of GW management up to 2012, and to determine the cost by UK jurisdiction. METHODS: Population statistics were obtained from the Office of National Statistics for the UK, England and Wales; the General Register Office and 2011 census data for Scotland; and the Northern Ireland (NI) Statistics and Research Agency. Numbers of GW cases in genito-urinary medicine (GUM) clinics were obtained from the Health Protection Agency for the UK and England; the Information Services Division for Scotland; the Communicable Disease Surveillance Centre for Wales; and the Public Health Agency for NI. The number of cases treated in primary care was estimated from The Health Improvement Network database. Population statistics and GW cases were extrapolated by jurisdiction to 2012. The number of visits and therapy required for GW management were estimated by GUM experts for standard and hard-to-treat patients. Costs were obtained from the most recent National Health Service (NHS) Payment by Results tariffs, Personal Social Services Research Unit and British National Formulary. RESULTS: The model  estimated 220,779 GW cases in the UK, costing £58.42 million annually (£265 per patient). For England, 157,693 cases were estimated costing £41.72 million; for Scotland 7,461 cases costing £1.90 million; for Wales 7,091 cases costing £1.87 million; and for NI 3,619 cases costing £0.95 million. CONCLUSIONS: The full NHS costs for the management of GW have never before been estimated separately for each jurisdiction. The results of the model reveal a significant economic burden which is important to quantify when understanding the value of quadrivalent HPV vaccination.